

DAFTAR PUSTAKA

- Adigun, R., & Singh, R. (2023). *Tuberculosis*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK441916/>
- Arrang, S. T., & Widyati. (2018). The Incidence and Risk Factor Analysis of Drug Induced Liver Injury (Dili) in a Surabaya Hospital. *Galenika Journal of Pharmacy*, 4(2), 79–86. <https://doi.org/10.22487/j24428744.2017.v4.i2.10459>
- Azmi, R. N., Ardiani, T., & Siami, S. (2022). Perbedaan Nilai Enzim Transaminase dan Derajat Keparahan Hepatotoksik pada Penggunaan Obat Antituberkulosis Studi Cross Sectional pada Pasien Tuberkulosis dan Pasien Koinfeksi Tuberkulosis- Human Immunodeficiency Virus. *Medica Hospitalia*, 9(1), 37–42. <https://media.neliti.com/media/publications/505237-hepatotoxicity-related-to-anti-tuberculo-f8f81c2e.pdf>
- Banjuradja, I., & Singh, G. (2020). Mekanisme Hepatotoksisitas Dan Tatalaksana Tuberkulosis Pada Gangguan Hati. *Indonesia Journal Chest*, 7(2), 55–64. http://www.indonesiajournalchest.com/index.php/IJC/issue/view/mekanisme_hepatotoksisitas_dan_tatalaksana_tuberkulosis_pada_gangguan_hati/mekanisme_hepatotoksisitas_dan_tatalaksana_tuberkulosis_pada_gangguan_hati
- Bishop, M. L. (2020). *Clinical Chemistry Principles Techniques and Correlation* (Eighth). Burlington : Jones & Bartlett Learning. <http://ndl.ethernet.edu.et/bitstream/123456789/9683/1/124.pdf>
- Clarasanti, I., Wongkar, M. C. P., & Waleleng, B. J. (2016). Gambaran enzim transaminase pada pasien tuberkulosis paru yang diterapi dengan obat-obat anti tuberkulosis di RSUP Prof. Dr. R. D. Kandou Manado. *Jurnal E-Clinic*, 4(1), 1–6. <https://doi.org/https://doi.org/10.35790/ecl.v4i1.12102>
- Dasuki, A. A., Muti, A. F., & Yusmaini, H. (2020). Faktor Resiko Kejadian Peningkatan Kadar Transminase Pada Penggunaan Obat Antituberkulosis Pasien Tuberkulosis Paru di RST Wijayakusuma Purwokerto Artikel Penelitian. *Jurnal Farmasi Indonesia*, 12(1), 134–144.
- Dwipayana, I. M. G. (2022). Mengenali Gambaran Penyakit Tuberkulosis Paru Dan Cara Penanganannya. *E-Jurnal Widya Kesehatan*, 4(1), 1–14. <https://doi.org/https://doi.org/10.32795/widyakesehatan.v4i1.2806>

- Eddabra, R., & Neffa, M. (2020). Epidemiological profile among pulmonary and extrapulmonary tuberculosis patients in Laayoune, Morocco. *The Pan African Medical Journal*, 37, 56. <https://doi.org/10.11604/pamj.2020.37.56.21111>
- Francis, P., & Navarro, V. (2022). *Drug-Induced Hepatotoxicity*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK557535/>
- Gotera, W., Ida Bagus Aditya Nugraha, & Yustin, W. E. F. (2021). Diabetes Melitus sebagai Faktor Risiko Tuberkulosis. *Jurnal Kedokteran Meditek*, 27(3 SE-Tinjauan Pustaka), 273–281. <https://doi.org/10.36452/jkdoktmeditek.v27i3.2126>
- Hasanah, N., Ratnaningtyas, T. O., & Razana, A. (2020). Pengaruh Obat Anti Tuberkulosis terhadap Nilai SGPT dan SGOT Berdasarkan Usia dan Jenis Kelamin Pasien Tuberkulosis Paru di RS Sari Asis Ciputat. *Parapemikir : Jurnal Ilmiah Farmasi*, 9(2), 10–16. <https://doi.org/10.30591/pjif.v>
- Hussain, Z., Zhu, J., & Ma, X. (2021). Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug. *Drug Metabolism And Disposition*, 49(August), 679–682. <https://doi.org/https://doi.org/10.1124/dmd.121.000389>
- Irianti, T. T., & Kuswandi. (2016). *Mengenal Anti-Tuberkulosis. Cetakan Pertama*. Yogyakarta : CV Mine.
- Juliarta, I. G., Mulyantari, N. K., Putu, I. W., & Yasa, S. (2018). Gambaran Hepatotoksisitas (ALT / AST) Penggunaan Obat Anti Tuberkulosis Lini Pertama Dalam Pengobatan Pasien Tuberkulosis Paru Rawat Inap Di RSUP Sanglah Denpasar Tahun 2014. *E-Jurnal Medika*, 7(10). <https://ojs.unud.ac.id/index.php/eum/article/download/42757>
- Kemenkes. (2011). *Pedoman Nasional Pengendalian Tuberkulosis*. Jakarta : Kementerian Kesehatan Republik Indonesia.
- Kemenkes. (2016). *Peraturan Menteri Kesehatan Republik Indonesia Nomor 67 tahun 2016 Tentang Penanggulangan Tuberkulosis*. Jakarta : Kementerian Kesehatan Republik Indonesia.
- Kemenkes. (2020). *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis*. Jakarta : Kementerian Kesehatan Republik Indonesia.

- Kemenkes RI. (2023). *Laporan Program Penanggulangan Tuberkulosis Tahun 2022*. Jakarta : Kementerian kesehatan Republik Indonesia.
- Kim, J.-H., Nam, W. S., Kim, S. J., Kwon, O. K., Seung, E. J., Jo, J. J., Shresha, R., Lee, T. H., Jeon, T. W., Ki, S. H., Lee, H. S., & Lee, S. (2017). Mechanism Investigation of Rifampicin-Induced Liver Injury Using Comparative Toxicoproteomics in Mice. *International Journal of Molecular Sciences*, 18(7). <https://doi.org/10.3390/ijms18071417>
- Kumar, P. S., Vidya, R., Tabassum, & Jageer, M. (2020). Anti-Tuberculosis Treatment: Induced Hepatotoxicity - A Case Report. In *EJIFCC* (Vol. 31, Issue 3, pp. 242–247). <https://pubmed.ncbi.nlm.nih.gov/33061879/>
- Lolong, D. B., Aryastami, N. K., Kusriani, I., Tobing, K. L., Tarigan, I., Isfandari, S., Senewe, F. P., Raflizar, Endah, N., Sitorus, N., Pangaribuan, L., Simarmata, O. S., & Ariati, Y. (2023). Nonadherence to anti-tuberculosis treatment, reasons and associated factors among pulmonary tuberculosis patients in the communities in Indonesia. *PloS One*, 18(8), e0287628. <https://doi.org/10.1371/journal.pone.0287628>
- Mar'iyah, K., & Zulkarnain. (2021). Patofisiologi penyakit infeksi tuberkulosis. *Jurnal UIN Alauddin Makassar*, November, 88–92. <https://doi.org/https://doi.org/10.24252/psb.v7i1.23169>
- Metushi, I., Uetrecht, J., & Phillips, E. (2016). Mechanism of isoniazid-induced hepatotoxicity: then and now. *British Journal of Clinical Pharmacology*, 8. <https://doi.org/10.1111/bcp.12885>
- Ningsih, A. S. W., Ramadhan, A. M., & Rahmawati, D. (2022). Kajian Literatur Pengobatan Tuberkulosis Paru dan Efek Samping Obat Antituberkulosis di Indonesia. *Proceeding of Mulawarman Pharmaceuticals Conferences*, 27–29. <https://doi.org/https://doi.org/10.25026/mpc.v15i1.647>
- Nugraha, G., & Badrawi, I. (2018). *Pedoman Teknik Pemeriksaan Laboratorium Klinik*. Jakarta : Trans Info Media.
- Octrisdey, K. (2023). Analisis Bilirubin Dan Albumin Pada Penderita TB Tahap Awal Pengobatan Dan Tahap Akhir Menjalani Pengobatan. *An-Najat : Jurnal Ilmu Farmasi Dan Kesehatan*, 1(4).

- Padda, I., & Reddy, K. (2023). *Antitubercular Medications*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK557666/>
- Pratiwi, E. P., Rohmawaty, E., & Kulsum, I. D. (2018). Efek Samping Obat Anti Tuberkulosis Kategori I dan II Pasien Tuberkolosis Paru Dewasa di Rumah Sakit Hasan Sadikin. *Indonesian Journal of Clinical Pharmacy*, 7(4), 252. <https://doi.org/10.15416/ijcp.2018.7.4.252>
- Putri, T. M., & Widodo. (2021). Kadar SGOT , SGPT , dan Bilirubin Total pada Pasien Tuberkulosis Paru. *Jurnal Laboratorium Medis (JLM)*, 03(01), 13–23.
- Putri, W. R., Widada, S. T., & Setiawan, B. (2021). Penurunan Kadar Bilirubin Total Serum Yang Diencerkan Pada Penderita Tuberkulosis. *Jurnal Analisis Laboratorium Medik*, 6(1), 23–28. <https://doi.org/https://doi.org/10.51544/jalm.v6i1.1725>
- Rahayu, S. E. (2018). Hubungan Kadar SGOT-SGPT Pada Pasien TB Pengobatan Fase Awal Di Puskesmas Pati. *Repository Universitas Muhamamadiyah Semarang*. [http://repository.unimus.ac.id/3235/1/JURNAL MANUSCRIPT.pdf](http://repository.unimus.ac.id/3235/1/JURNAL%20MANUSCRIPT.pdf)
- Rahman, M. M., Setyawati, T., Sarifuddin, & Wahyuni, R. D. (2023). Mekanisme OAT Dalam Tubuh Yang Mengakibatkan Risiko DILI (Drug-Induced Liver Injury) : Literature Review. *Jurnal Medical Profession (MedPro)*, 5(1), 41–47. <https://jurnal.fk.untad.ac.id/index.php/medpro/article/view/869/455>
- Rasyid, S. A., Armayani, Yuniati, & Lio, T. M. P. (2020). Analysis of serum glutamic pyruvic transaminase and serum glutamic oxaloacetic transaminase levels in tuberculosis patients who are undergoing oat treatment in Kendari City General Hospital, Kota Kendari, Indonesia. *Infectious Disease Reports*, 12(Suppl 1), 8737. <https://doi.org/10.4081/idr.2020.8737>
- Rosida, A. (2016). Pemeriksaan Laboratorium Penyakit Hati. *Berkala Kedokteran*, 12(1), 123. <https://doi.org/10.20527/jbk.v12i1.364>
- Santoso, R., Susilawati, E., & Susanti, E. (2021). Analisa Pola Penggunaan Dan Kepatuhan Obat Tuberkulosis Di Salah Satu Rumah Sakit Swasta Di Kota Bandung. *Jurnal IKRA-ITH TEKNOLOGI*, 5(2), 58–71. <https://journals.upi-yai.ac.id/index.php/ikraith-teknologi/article/view/970/759>

- Sarkar, S., Ganguly, A., & Sunwoo, H. H. (2016). Current Overview of Anti-Tuberculosis Drugs: Metabolism and Toxicities Mycobacterial Diseases. *Mycobacterial Diseases Sarkar*, 6(2), 1–6. <https://doi.org/10.4172/2161-1068.1000209>
- Soedarsono, Mandayani, S., Prayuni, K., & Yuliwulandari, R. (2018). The Risk Factors For Drug Induced Hepatitis In Pulmonary Tuberculosis Patients In Dr. Soetomo Hospital. *Indonesian Journal of Tropical and Infectious Disease*, 7(3), 73–79. <https://doi.org/https://doi.org/10.20473/ijtid.v7i3.8689>
- Sunarmi, & Kurniawaty. (2022). Hubungan Karakteristik Pasien TB Paru Dengan Kejadian Tuberkulosis. *Jurnal 'Aisyiyah Medika*, 7, 182–187.
- Suprpto. (2018). Pengetahuan Dan Sikap Masyarakat Dalam Upaya Pencegahan Tuberkulosis Di Wilayah Kerja Puskesmas Batua Kota Makassar. *Jurnal Ilmiah Kesehatan Sandi Husada*, 7(2), 1114–1124. <https://doi.org/https://doi.org/10.35816/jiskh.v7i1.10>
- Syalia, T. P., Widada, N. S., & Ritonga, A. F. (2022). Pemeriksaan Kadar SGOT SGPT Pada Lansia Penderita Tuberkulosis. *Binawan Student Journal (BSJ)*, 4(April), 9–13. <https://doi.org/https://doi.org/10.54771/bsj.v4i1.215>
- Wang, P., Pradhan, K., Zhong, X.-B., & Ma, X. (2016). Isoniazid metabolism and hepatotoxicity. *Acta Pharmaceutica Sinica. B*, 6(5), 384–392. <https://doi.org/10.1016/j.apsb.2016.07.014>
- Yorke, E., Atiase, Y., Akpalu, J., Sarfo-Kantanka, O., Boima, V., & Dey, I. D. (2017). The Bidirectional Relationship between Tuberculosis and Diabetes. *Tuberculosis Research and Treatment*, 2017, 1702578. <https://doi.org/10.1155/2017/1702578>
- Zelege, A., Misiker, B., & Yesuf, T. A. (2020). Drug-induced hepatotoxicity among TB/HIV co-infected patients in a referral hospital, Ethiopia. *BMC Research Notes*, 13(1), 2. <https://doi.org/10.1186/s13104-019-4872-1>